Reexcision rates after partial mastectomy vary greatly

Share this article:
Reexcision rates after partial mastectomy vary greatly
Reexcision rates after partial mastectomy vary greatly

Nearly one-fourth of women who undergo a partial mastectomy have a second surgery to remove additional tissue, and there is substantial surgeon and institutional variation in the rate of reexcisions that cannot be explained by patients' clinical characteristics.

Investigators reached this conclusion after conducting an observational study of breast surgery performed between 2003 and 2008 at four medical institutions (JAMA. 2012;307[5]:467-475). Of 2,206 women (mean age 62 years) with 2,220 newly identified invasive breast cancers who underwent a partial mastectomy, 509 of them (22.9%) had additional surgery. Most patients (454, or 89.2%) had one reexcision, 48 women (9.4%) had two reexcisions, and seven women (1.4%) had three reexcisions.Of the full group of women, 190 (8.5%) eventually had a total mastectomy.

Failure to achieve appropriate surgical margins (the rim of normal tissue around the cancerous tissue) after initial partial mastectomy results in the need for more surgery. Reexcision rates for margin status after the first operation were as follows:

  • 85.9% for initial positive margins
  • 47.9% for margins of less than 1.0 mm
  • 20.2% for margins of 1.0 to 1.9 mm
  • 6.3% for margins of 2.0 to 2.9 mm.

Reexcision rates varied widely among surgeons and institutions for patients with negative surgical margins. The great variation in reexcision rates could not be explained by a patient's medical or treatment history.

As the investigators point out, partial mastectomy is the most commonly performed procedure for invasive breast cancer, and cancer recurrence as well as the patient's overall survival could possibly be affected by differences in initial surgical care.

“The wide level of unexplained clinical variation itself represents a potential barrier to high-quality and cost-effective care of patients with breast cancer,” cautioned study leader Laurence E. McCahill, MD, director of surgical oncology at The Lacks Cancer Center in Grand Rapids, Michigan, in a statement describing his group's findings. 

Share this article:
You must be a registered member of ONA to post a comment.

Next Article in Web Exclusives

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

'Electronic skin' could improve early breast cancer detection

Scientists are now developing an "electronic skin" that will aid in the detection of breast masses.

Disparities persist in early stage breast cancer treatment

Despite its acceptance as standard of care neary 25 years ago, barriers still exist that preclude patients from receiving breast conserving therapy (BCT), according to research presented at the ASCO 2014 Breast Cancer Symposium.

Adding drugs to standard chemotherapy improves response in triple-negative breast cancer

Adding carboplatin and/or bevacizumab to the standard treatment regimen significantly improved pathologic complete response rates in patients with triple-negative breast cancer, according to a new phase 2 study.